

PANEL CENTURY DIAGNÓSTICO TUMORAL (CDT).

Somatic and germline mutations

Panel that allow to know the **nature of each tumor** in an individual and personalized way, through the study of **tumoral tissue** and **normal tissue** (blood) of the patient.

CAP and **CLIA** accreditation.

Determination of tumor mutational burden (**TMB**). The tumor mutational burden (TMB) is identified as reliable predictive biomarker for responses to treatment with **immune checkpoint** blockade. It is used to classify tumors into groups with low, medium and high mutational load.

MSI (microsatellite instability) is another important parameter for response to **immune checkpoint** blockade.

Sample Requirements:

Normal tissue: EDTA blood or Genomic DNA

Tumor tissue: FFPE tumor block or FFPE tumor tissue slides.

Liquid biopsy: cfDNA tubes for liquid biopsy

Complete sequencing of **742** genes (NGS) and 31 translocations in specific genes.

Clinical report that mutations detected are associated with **current treatments, clinical trials...** providing counselling and **support** to the clinician in therapeutic decision-making (**FDA** and **EMA** approved).

In tumors copy number variations (**CNVs**) are frequent due to the overall genomic instability.

It is important to understand these deletions/amplifications and know the genes in the affected region with therapeutic relevance.

The panel can also be performed on **Liquid Biopsy** samples, to see mutations in circulating free tumor DNA (**cfDNA**) in the patient's blood

